Molecular design of hybrid tumour necrosis factor-ac II: the molecular size of polyethylene glycol-modified tumour necrosis factor-ac affects its anti-tumour potency
1996

Designing a Better Tumor Treatment with Modified TNF-alpha

Sample size: 9 publication Evidence: moderate

Author Information

Author(s): Y Tsutsumi, S Tsunoda, H Kamada, T Kihira, S Nakagawa, Y Kaneda, T Kanamori, T Mayumi

Primary Institution: Osaka University

Hypothesis

The molecular size of polyethylene glycol-modified tumor necrosis factor-alpha affects its anti-tumor potency.

Conclusion

Larger molecular sizes of modified TNF-alpha significantly enhance its anti-tumor effects compared to native TNF-alpha.

Supporting Evidence

  • PEG-modified TNF-alpha showed over ten times greater anti-tumor effects than native TNF-alpha.
  • The optimal modification of TNF-alpha with PEG5000 significantly increased its anti-tumor potency.
  • Complete regression of tumors was observed in some mice treated with modified TNF-alpha.
  • Modified TNF-alpha had a prolonged plasma half-life compared to native TNF-alpha.

Takeaway

Scientists are trying to make a medicine that fights tumors better by changing its size with a special ingredient called PEG.

Methodology

The study involved modifying TNF-alpha with different sizes of polyethylene glycol and testing their effects on tumor cells in mice.

Limitations

The study primarily focused on in vivo effects without extensive clinical trials.

Participant Demographics

Male ddY mice, 5 weeks old.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication